MedPath

The Long COVID-19 Wearable Device Study

Not Applicable
Recruiting
Conditions
Dysautonomia
Postural Orthostatic Tachycardia Syndrome
Chronic Fatigue Syndrome
Long Covid19
Long COVID
Myalgic Encephalomyelitis
Registration Number
NCT05741112
Lead Sponsor
Scripps Translational Science Institute
Brief Summary

To further characterize Long COVID-19 by collecting data from individuals who already own wearable devices or are provided with a wearable device along with basic and enhanced educational materials to determine if both can improve Long COVID-19 symptom management and post-exertional malaise.

Detailed Description

This study will have two components:

One study group will consist of up to 100,000 individuals who own wearable devices and are willing to share their data. These participants will be randomized and will receive educational materials. The investigators will study these dynamic wearable data along with participant survey responses that focus on diagnoses, symptoms, and quality of life to improve disease characterization and understanding of differences within and between individuals.

The other group in the randomized trial will participants who do not already own a wearable device. The study will distribute wearable devices and pacing educational materials to 500 individuals who do not already own them and experience post-exertional malaise, or the worsening of symptoms following exertion.

The investigators hypothesize that access to personalized information from a wearable device will enable participants to reduce post-exertional malaise. The investigators will include up to 25% individuals whose post-exertional malaise is caused by a condition other than Long COVID-19.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100500
Inclusion Criteria
  • Is at least 18 years old.
  • Has a self/and or physician diagnosis of:
  • Long COVID (based on the WHO working definition),
  • ME/CFS (myalgic encephalomyelitis / chronic fatigue syndrome, self-diagnosis based on IOM criteria), and/or
  • POTS (Postural Orthostatic Tachycardia Syndrome).
  • Is interested in tools to manage ME/CFS, POTS, and/or Long COVID symptoms.
  • Owns a wearable device they are willing to use for this study or does not own a device and agrees to utilize a study-provided one.
  • Agrees to wear the device throughout the study period, share the data with the study, and sync data at least weekly.
  • Has access to a smartphone or tablet to enable syncing wearable data and viewing device feedback.
  • Agrees to disclose involvement in other ME/CFS, POTS, and/or Long COVID interventions such as medical treatment, self-management, and other interventional studies.
  • Agrees to complete at least 75% of the study surveys.
Exclusion Criteria
  • As long as they meet inclusion there is no exclusion

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Primary Objective 1:Assess the effect of study-provided devices and enhanced educational materials to manage Long COVID-19 symptom severity, compared to general educational materials alone using data from participants survey responses.3 months

Will measure relapse symptom frequency, symptom severity, pain, quality of life and overall health through the analysis and measurement of change in the weekly survey responses.

Primary Objective 2: Collate a unique longitudinal dataset combining patients' demographics, symptoms, symptom severity, quality of life, and sensor data including sleep, activity, heart rate, heart rate variability, and Body Battery.12 months

Will measure relapse symptom frequency, symptom severity, pain, quality of life and overall health through the analysis and measurement of change from the baseline survey to the quarterly survey.

Secondary Outcome Measures
NameTimeMethod
Secondary Objective: Assess the longitudinal impact of sustained use of the study-provided devices and enhanced educational materials on symptom severity.12 months

Conduct within-subject comparisons on the primary and secondary endpoints listed above but such that the investigators are assessing the change between the baseline measurement at month zero and that of the quarterly survey nine months after the distribution of the device and/or enhanced education materials.

Trial Locations

Locations (1)

Scripps Research

🇺🇸

La Jolla, California, United States

Scripps Research
🇺🇸La Jolla, California, United States
Andrea Goosen
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.